NCT07251712 Single and Multiple Dose Pharmacokinetics (PK) of Aramchol From an Aramchol Meglumine Tablet
| NCT ID | NCT07251712 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Galmed Pharmaceuticals Ltd |
| Condition | Healthy |
| Study Type | INTERVENTIONAL |
| Enrollment | 32 participants |
| Start Date | 2025-12-25 |
| Primary Completion | 2026-04-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 32 participants in total. It began in 2025-12-25 with a primary completion date of 2026-04-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Evaluate the exposure of of Aramchol from 2 different single doses of Aramchol meglumine tablet and to compare the exposure of steady state from a selected dose of Aramchol meglumine tablet.
Eligibility Criteria
Inclusion Criteria: * Male or female healthy volunteers with body mass index (BMI) in the range of 18-30.9 kg/ m2 inclusive * Deemed healthy on the basis of clinical history, physical examination, ECG, vital signs, and laboratory tests of blood and urine * Agree to follow-up the contraception requirements of the trial * Able to give fully informed written consent Exclusion Criteria: * Females of reproductive potential who are pregnant or lactating * Positive tests for hepatitis B, C or HIV * History of sever adverse reaction to any drug * Known sensitivity to drug medication * Drug or alcohol abuse * Smoking in the 3 months prior the study * Clinically relevant abnormal lab results, medical history or concurrent medical condition * Evidence of acute or chronic disease * Inability to adhere to study requirements
Contact & Investigator
Christina Yeung, MBBS
PRINCIPAL INVESTIGATOR
Hammersmith Medicines Research
Frequently Asked Questions
Who can join the NCT07251712 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 55 Years, studying Healthy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07251712 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07251712 currently recruiting?
Yes, NCT07251712 is actively recruiting participants. Contact the research team at yossigs@galmedpharma.com for enrollment information.
Where is the NCT07251712 trial being conducted?
This trial is being conducted at London, United Kingdom.
Who is sponsoring the NCT07251712 clinical trial?
NCT07251712 is sponsored by Galmed Pharmaceuticals Ltd. The principal investigator is Christina Yeung, MBBS at Hammersmith Medicines Research. The trial plans to enroll 32 participants.